Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DMA7E5
|
|||
| Drug Name |
PF-07261271
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Inflammatory bowel disease [ICD-11: DD72; ICD-10: K50-K52] | Phase 1 | [1] | |
| Company |
Pfzer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-12 beta (IL12B) | Target Info | . | [2] |
| Vascular endothelial cell growth inhibitor (TNFSF15) | Target Info | . | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Toll-like receptor signaling pathway | ||||
| RIG-I-like receptor signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Type I diabetes mellitus | ||||
| Pertussis | ||||
| Legionellosis | ||||
| Leishmaniasis | ||||
| Chagas disease (American trypanosomiasis) | ||||
| African trypanosomiasis | ||||
| Malaria | ||||
| Toxoplasmosis | ||||
| Amoebiasis | ||||
| Tuberculosis | ||||
| Measles | ||||
| Influenza A | ||||
| Herpes simplex infection | ||||
| Inflammatory bowel disease (IBD) | ||||
| Allograft rejection | ||||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Allograft Rejection | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05536440) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE INTRAVENOUS AND MULTIPLE SUBCUTANEOUS AND INTRAVENOUS DOSES OF PF-07261271 IN HEALTHY PARTICIPANTS. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Pfizer | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.